Overview
PHAT market data
Price History
PHAT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.03 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -41.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.21 – $18.31 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $693.3M · P/B 8.32 · P/S 2.89.
Company News
Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22Benzinga · Jul 31, 2026, 2:12 PM
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price TargetBenzinga · Jul 31, 2026, 10:06 AM
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22Benzinga · Jul 30, 2026, 7:24 PM
Phathom Pharmaceuticals shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance below analyst estimates.Benzinga · Jul 30, 2026, 5:39 PM
Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M EstimateBenzinga · Jul 30, 2026, 11:14 AM
8-K filing — Phathom Pharmaceuticals, Inc. (PHAT)SEC EDGAR · Jul 30, 2026, 11:05 AM
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M EstBenzinga · Jul 30, 2026, 11:01 AM
Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M EstimateBenzinga · Jul 30, 2026, 10:59 AM
Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In AdultsBenzinga · Jun 23, 2026, 12:05 PM